BioPortfolio Blog about Biotechnology, Pharmaceutical and Healthcare

Mental Health Awareness Week 2013

The 13-19th May in the UK is Mental Health Awareness Week, a week where the Mental Health Foundation runs national campaigns looking at mental health, and this year specifically, the impact of exercise and physical activity on mental health and wellbeing. Since endorphins were discovered, it has been well known that exercise can give you a feel-good factor. But the wider impact and potential...

Edison Investment - Circadian Technologies - New VGX-300 data - I spy Eylea

May 13th 2013: Circadian’s retinal therapy subsidiary, Opthea, has published a preclinical study into VGX-300, an anti-VEGF-C trap biological entity based on an engineered antibody structure. This excellent data, showing equivalence to Eylea, may be pivotal in gaining a rapid partnering deal for VGX-300, enabling it to target the booming $2.6bn Lucentis/Eylea duopoly in wet age-related mac...

Edison Investment - Lombard Medical - Full-year results - US launch in sight

May 13th 2013: Lombard Medical has reached a pivotal stage as it gears up to launch Aorfix, its AAA stent graft for aortic neck angles from 0-90°. Aorfix has significant commercial potential and will compete with devices from the established US medtech companies on the basis of its unique label. The size of the US market, with over 50% of global EVAR volumes, means that sales of Aorfix could...

Edison Investment - NovaBay Pharmaceuticals - Q113 sets the scene - Tuning in for a crescendo of data

NovaBay’s Q113 results set the scene for a potentially transformational second half of 2013, with results expected from three Phase II studies of its topical anti-infective, auriclosene (NVC-422). We currently value the company at $71m, or $1.90 per share, but successful outcomes in all three trials (urinary catheter irrigation, impetigo and viral conjunctivitis, in order of increasing val...

Edison - Athersys - Investment summary: Gathering momentum

Athersys’ stock has gained 25% in the last month to trade at an 18-month high. We believe positive biotech sentiment in general, and burgeoning interest in stem cells and regenerative medicine in particular, are contributory factors. For Athersys, the key near-term catalyst is headline data in Q413 from a Phase II study of its MultiStem product (allogeneic stem cells from adult bone marrow...